The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.9 Announcement

2 Dec 2020 11:51

RNS Number : 2990H
Horizon Discovery Group plc
02 December 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

For immediate release

2 December 2020

Horizon Discovery Group plc 

("Horizon" or the "Company")

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Horizon confirms that, on 2 December 2020 (the date of this announcement), it has 158,363,934 ordinary shares of £0.01 each in issue and admitted to trading on AIM. The International Securities Identification Number ("ISIN") for the Company's ordinary shares is GB00BK8FL363.

Enquiries:

Horizon

Terry Pizzie, Chief Executive Officer Tel: +44 (0) 12 2365 5580 Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Evercore (Lead Financial Adviser to Horizon)

Simon Elliott Tel: +44 (0) 20 7653 6000

Edward Banks

Numis (Joint Financial Adviser, Broker and NOMAD to Horizon)

Freddie Barnfield Tel: +44 (0) 20 7260 1000

Stuart Ord Duncan Monteith

Consilium Strategic Communications (Financial Media and UK Investor Relations Adviser to Horizon)

Mary-Jane Elliott Tel: +44 (0) 7720 088 468

Matthew Neal Melissa Gardiner

 

Disclaimer

Evercore Partners International LLP ("Evercore"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively as financial adviser to Horizon and no one else in connection with the matters described in this Announcement and will not be responsible to anyone other than Horizon for providing the protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, in delict, under statute or otherwise) to any person who is not a client of Evercore in connection with this Announcement, any statement contained herein, any offer or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by the Financial Services and Markets Act 2000, or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility or liability whatsoever for the contents of this Announcement, and no representation, express or implied, is made by it, or purported to be made on its behalf, in relation to the contents of this Announcement, including its accuracy, completeness or verification of any other statement made or purported to be made by it, or on its behalf, in connection with Horizon or the matters described in this document. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, in delict, contract or otherwise (save as referred to above) which they might otherwise have in respect of this Announcement or any statement contained herein.

Numis Securities Limited ("Numis"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for Horizon and no one else in connection with the matters set out in this Announcement and will not regard any other person as its client in relation to the matters in this Announcement and will not be responsible to anyone other than Horizon for providing the protections afforded to clients of Numis, nor for providing advice in relation to any matter referred to herein.

 

Publication on website

In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions), free of charge, on the Company's website at www.horizondiscoveryplc.com by no later than 12:00 noon on the business day following the date of this announcement. Neither the content of this website nor the content of any other website accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTKKBBPDBDDKBK
Date   Source Headline
25th Mar 20157:00 amRNSHorizon Discovery awarded AMSCI grant
24th Mar 20157:00 amRNSNotice of Preliminary Results
23rd Mar 20157:00 amRNSHorizon Discovery and ArcherDX Sign OEM Agreement
18th Mar 201510:39 amRNSAdditional Listing
11th Mar 20157:00 amRNSHorizon Provides Genomic Standards To CRUK
18th Feb 20157:00 amRNSInnovate UK funding award
11th Feb 20154:27 pmRNSAdditional Listing
5th Feb 201512:21 pmRNSAdditional Listing
2nd Feb 20157:00 amRNSHorizon Discovery Selected as Core Facility
27th Jan 201512:00 pmRNSAdditional Listing
23rd Jan 20154:46 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSRevenues expected to be ahead of consensus by 7%
15th Jan 20157:00 amRNSHolding(s) in Company
8th Jan 20157:00 amRNSAcquisition of Haplogen Genomics GmbH
30th Dec 20147:00 amRNSHorizon Discovery Group Signs Agreement for $810K
22nd Dec 20144:49 pmRNSAdditional Listing
19th Dec 20146:23 pmRNSHolding(s) in Company
8th Dec 20147:00 amRNSLaunch of Gene-Engineered Bioproduction Cell Line
26th Nov 20143:09 pmRNSHolding(s) in Company
24th Nov 20147:00 amRNSHorizon Enter Agreement with Adarza BioSystems
19th Nov 201412:26 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNS$750,000 contract win from top ten pharma
3rd Nov 20147:00 amRNSAppoints Dr David Smoller as an Executive Director
15th Oct 20147:00 amRNSHorizon CombinatoRx Wins Contract
6th Oct 20143:14 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Oct 20147:00 amRNSCo-Exclusive Commercial Agreement Signed
29th Sep 20147:00 amRNSAcquires Sage Labs Inc. for $48M (£29M)
25th Sep 201412:30 pmRNSAdditional Listing
25th Sep 20147:00 amRNS$1.2 million Master Services Agreement
23rd Sep 20147:00 amRNSInterim Results for Six Months Ended 30 June 2014
17th Sep 20144:34 pmRNSHolding(s) in Company
15th Sep 20145:29 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th Sep 201410:17 amRNSAdditional Listing
3rd Sep 20147:00 amRNSNotice of Interim Results
5th Aug 20147:00 amRNSCRISPR Experts Join Scientific Advisory Board
28th Jul 20143:57 pmRNSAdditional Listing
25th Jul 20147:00 amRNSHZD sign Collaboration Agreement with Otsuka
23rd Jul 20147:00 amRNSTrading Update
3rd Jul 20147:00 amRNSLicenses AAV Gene Delivery Technology
19th Jun 201410:48 amRNSDirector/PDMR Shareholding
17th Jun 20143:35 pmRNSAdditional Listing
16th Jun 20147:00 amRNSTSB Grant for next generation cancer diagnostics
12th Jun 20147:00 amRNSLicenses CRISPR Technology from Broad Institute
11th Jun 201412:11 pmRNSDirector/PDMR Shareholding
9th Jun 20147:00 amRNSAppointment of two Non-Executive Directors
2nd Jun 20147:00 amRNSCompletion of Acquisition of CombinatoRx
15th May 20147:00 amRNSAcquisition
8th May 20147:00 amRNSHolding in Company
8th May 20147:00 amRNSLicenses Gene Editing Technology from ERS Genomics
6th May 20145:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.